Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes

待确认 20 由李秀发布于 2026/4/14 9:01:59

DOI:10.1182/blood-2020-136935
作者：J. Zeidner, F. Mazerolle, J. Bell, L. Cain, D. Faller, M. Dalal, A. Regnault, R. Fram
文献类型：期刊论文
补充材料：只需要正文

American Society of Hematology (ASH)

Abstract：Introduction P-2001, a randomized phase 2 trial (NCT02610777), investigated the efficacy and safety of pevonedistat (P), the first small-molecule inhibitor of the NEDD8-activating enzyme, i

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

17小时前

季季宝

202604141108376333544.pdf

19小时前

Book学术机器人

2026/4/14 9:01:59 未找到该文献，机器人已退出，请等待人工下载

2026/4/14 9:01:59 Book学术AI机器人收到请求，开始寻找文献

2026/4/14 9:01:59 已向机器人发送请求

19小时前

李秀发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Society of Hematology (ASH)Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia